Collegium Pharmaceutical (NASDAQ:COLL) Given New $42.00 Price Target at Truist Financial

Collegium Pharmaceutical (NASDAQ:COLL) had its price target raised by Truist Financial from $40.00 to $42.00 in a research report sent to investors on Friday, Benzinga reports. Truist Financial currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on the company. Jefferies Financial Group upgraded Collegium Pharmaceutical from a hold rating to a buy rating and raised their price objective for the company from $41.00 to $44.00 in a research note on Friday, June 7th. HC Wainwright raised Collegium Pharmaceutical from a neutral rating to a buy rating and set a $47.00 price objective for the company in a report on Tuesday, July 30th. Piper Sandler reissued a neutral rating and issued a $37.00 price objective (down previously from $39.00) on shares of Collegium Pharmaceutical in a report on Friday. StockNews.com lowered Collegium Pharmaceutical from a strong-buy rating to a buy rating in a report on Wednesday, May 1st. Finally, Needham & Company LLC reissued a hold rating on shares of Collegium Pharmaceutical in a report on Friday. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of Moderate Buy and an average target price of $42.00.

Collegium Pharmaceutical Stock Up 0.5 %

Shares of COLL traded up $0.18 during trading hours on Friday, reaching $35.50. The stock had a trading volume of 413,104 shares, compared to its average volume of 471,066. Collegium Pharmaceutical has a 12 month low of $20.95 and a 12 month high of $40.95. The firm has a 50-day simple moving average of $33.09 and a 200 day simple moving average of $34.84. The company has a current ratio of 1.21, a quick ratio of 1.14 and a debt-to-equity ratio of 1.98. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of 14.79 and a beta of 0.93.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The company had revenue of $145.28 million for the quarter, compared to analysts’ expectations of $143.94 million. During the same period last year, the business earned $1.13 EPS. Collegium Pharmaceutical’s quarterly revenue was up 7.2% compared to the same quarter last year. Equities research analysts predict that Collegium Pharmaceutical will post 5.73 earnings per share for the current fiscal year.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, Director Garen G. Bohlin sold 28,985 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $32.30, for a total value of $936,215.50. Following the completion of the transaction, the director now owns 44,775 shares in the company, valued at $1,446,232.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Garen G. Bohlin sold 28,985 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $32.30, for a total transaction of $936,215.50. Following the sale, the director now directly owns 44,775 shares of the company’s stock, valued at $1,446,232.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Colleen Tupper sold 19,710 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total value of $674,279.10. Following the completion of the transaction, the chief financial officer now directly owns 130,845 shares in the company, valued at $4,476,207.45. The disclosure for this sale can be found here. Insiders sold a total of 105,502 shares of company stock worth $3,540,796 over the last quarter. 3.98% of the stock is owned by corporate insiders.

Institutional Trading of Collegium Pharmaceutical

A number of large investors have recently added to or reduced their stakes in COLL. Renaissance Technologies LLC boosted its holdings in Collegium Pharmaceutical by 8.0% during the 2nd quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock valued at $49,314,000 after acquiring an additional 113,300 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Collegium Pharmaceutical by 2.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,039,024 shares of the specialty pharmaceutical company’s stock worth $33,457,000 after acquiring an additional 19,876 shares in the last quarter. BOKF NA acquired a new position in Collegium Pharmaceutical during the 2nd quarter valued at about $490,000. American Century Companies Inc. increased its position in Collegium Pharmaceutical by 8.8% during the 2nd quarter. American Century Companies Inc. now owns 99,808 shares of the specialty pharmaceutical company’s stock valued at $3,214,000 after buying an additional 8,097 shares in the last quarter. Finally, Choreo LLC acquired a new position in Collegium Pharmaceutical during the 2nd quarter valued at about $396,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.